![Foto de Antonio](/img/nophoto.png)
Antonio
Llombart Cussac
Publicacións nas que colabora con Antonio Llombart Cussac (13)
2021
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394
2019
-
Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study
Clinical Breast Cancer, Vol. 19, Núm. 2, pp. 105-112
-
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Scientific Reports, Vol. 9, Núm. 1
2016
2011
-
Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer
Anti-Cancer Drugs, Vol. 22, Núm. 3, pp. 283-289
2010
-
Current controversies in the management of breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286
-
Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))
Clinical and Translational Oncology
2008
-
A single-nucleotide polymorphismin the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma
Clinical Cancer Research, Vol. 14, Núm. 3, pp. 811-816
-
Neoadjuvant endocrine therapy for breast cancer: Past, present and future
Anti-Cancer Drugs, Vol. 19, Núm. 4, pp. 339-347
-
Time-to-progression in breast cancer: A stratification model for clinical trials
Breast, Vol. 17, Núm. 3, pp. 239-244
2001
-
Circulating angiogenic growth factors as predictive factors in metastatic breast cancer treated with letrozole
Breast Cancer Research and Treatment, Vol. 69, Núm. 3, pp. 244
-
Serum HER-2 ECD and the efficacy of letrozole in ER+/ PR+ metastatic breast cancer: Preliminary results of a prospective study
Breast Cancer Research and Treatment, Vol. 69, Núm. 3, pp. 242